FDAsafety guidance72% confidence
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Roche.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Digital Pathology
- Sub-indication
- General
Related signal: Roche to Acquire PathAI for $750M to Enhance AI-Driven Diagnostics